NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗糖尿病藥物市場模型研究,分類類型(ALPHA-糖甘□抑制劑,特定分類,DPP-IV抑制性賦形劑,GLP-1促進劑和胰島素),疾病,患者(至2025年),COVID-19-歲的藥物。

Antidiabetic Drug Market Research Report by Type (Alpha-glucosidase Inhibitors, Biguanides, and DPP-IV Inhibitors), by Disease, by Patient, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 989539
出版日期 內容資訊 英文 181 Pages
商品交期: 最快1-2個工作天內
價格
抗糖尿病藥物市場模型研究,分類類型(ALPHA-糖甘□抑制劑,特定分類,DPP-IV抑制性賦形劑,GLP-1促進劑和胰島素),疾病,患者(至2025年),COVID-19-歲的藥物。 Antidiabetic Drug Market Research Report by Type (Alpha-glucosidase Inhibitors, Biguanides, and DPP-IV Inhibitors), by Disease, by Patient, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 181 Pages
簡介

全球抗糖尿病藥物市場預計將從2020年的35,298.17百萬美元增長到2025年底的56,1467.1百萬美元。

市場細分和覆蓋率

該研究對全球抗糖尿病市場進行了分類,預測了以下各個子市場的收入並分析了其趨勢:

  • 類型,抗糖尿病藥物市場包括ALPHA-葡萄糖甘□抑製劑,雙胍類,DPP-IV(二□基□□)抑製劑,GLP-1(胰高血糖素樣□)激動劑,胰島素,美格替尼,SGLT-II(鈉葡萄糖轉運蛋白)研究了抑製劑,磺□尿類和塞唑烷二酮類。進一步研究了中效胰島素,長效類似物,預混胰島素,速效類似物和短效類似物的胰島素。
  • 根據疾病,對1型和2型糖尿病之間的抗糖尿病藥物市場進行了調查。
  • 通過患者,對成人,老年人和兒童的抗糖尿病藥物市場進行了調查。
  • 按地區,在美國,亞太地區,歐洲,中東/非洲,阿根廷,巴西,加拿大,墨西哥和美國對抗糖尿病藥市場進行了調查。在亞太地區,在澳大利亞,中國,印度,印度尼西亞,日本,馬來西亞,菲律賓,韓國和泰國進行了調查。在歐洲,中東和非洲,對法國,德國,意大利,荷蘭,卡塔爾,俄羅斯,沙特阿拉伯,南非,西班牙,阿拉伯聯合酋長國和英國進行了調查。

COVID-19的累積影響

預計COVID-19將在預測期內對行業增長產生長期影響,因為這是無與倫比的全球公共衛生突發事件,幾乎影響了每個行業。我們正在進行的研究擴大了研究框架,以確保它包括潛在的COVID-19問題和潛在的未來路徑。該調查提供了對COVID-19的見解,並考慮了消費者行為和需求,購買模式,供應鏈改路,當前市場勢力動態以及政府的主要干預措施的變化。更新後的調查提供了見解,分析,估計和預測,其中考慮了COVID-19對市場的影響。

報告提供了有關以下準則的見解:

  • 1. 市場滲透率:主要參與者提供的全面市場信息
  • 2. 市場開發:有利可圖的新興市場的詳細信息和市場分析
  • 3. 市場多元化:有關新產品發佈,欠發達地區,最新發展和投資的更多信息
  • 4. 競爭評估和情報:全面評估領先公司的市場份額,戰略,產品和製造能力
  • 5. 產品開發和創新:對未來技術,研發活動和新產品開發的見解

報告回答以下問題:

  • 1. 全球抗糖尿病藥物市場的規模和預測是什麼?
  • 2. 在預測期內,將影響全球抗糖尿病藥物市場的COVID-19的抑製劑和影響是什麼?
  • 3. 在全球糖尿病藥物市場的預測期內,您將投資哪些產品/細分/應用/領域?
  • 4. 全球抗糖尿病市場中的機會競爭戰略窗口是什麼?
  • 5. 全球抗糖尿病市場趨勢技術趨勢和監管框架是什麼?
  • 6. 被認為適合進入全球糖尿病藥物市場的方式和戰略舉措是什麼?

本報告調查了抗糖尿病藥物市場,分析了市場概況,市場增長和障礙,市場規模趨勢以及按類型和地區,競爭狀況,主要公司的概況和市場預測的趨勢,並提供了諸如機遇之類的全面信息。

目錄

第1章簡介

  • 調查目的
  • 市場細分和覆蓋範圍
  • 調查目標年度
  • 貨幣和價格
  • 語言
  • 限制
  • 利益相關者

第2章調查方法

  • 調查過程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:測量設備
    • 集合:數據源
    • 分析:數據解釋
    • 公式:數據驗證
    • 發佈:調查報告
    • 重複:報告更新
  • 進行調查
    • 開始:調查過程
    • 計劃:創建調查計劃
    • 執行:進行調查
    • 驗證:發現和分析
    • 出版物:調查報告
  • 調查結果

第3章執行摘要

  • 簡介
  • 市場前景
  • 患者前景
  • Outlook的類型
  • 疾病前景
  • 區域展望
  • 競爭對手的展望

第4章市場概述

  • 簡介
  • COVID-19的累積效果

第5章市場洞察

  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
    • 挑戰
  • 波特五力分析
    • 新進入者的威脅
    • 替代威脅
    • 客戶的議價能力
    • 供應商的談判能力
    • 行業競爭

第6章按類型劃分的全球抗糖尿病市場

  • 簡介
  • ALPHA-葡萄糖甘□抑制劑
  • 雙胍
  • DPP-IV(二□基□□)抑制劑
  • GLP-1(胰高血糖素樣□)促進劑
  • 胰島素
    • 中級胰島素
    • 長效模擬
    • 預混胰島素
    • 速效類似物
    • 短效模擬
  • 美格力寧
  • SGLT-II(鈉葡萄糖轉運蛋白)□□抑制劑
  • 磺□尿劑
  • 塞唑烷二酮

第7章全球抗糖尿病藥市場:按疾病分類

  • 簡介
  • 1型糖尿病
  • 2型糖尿病

第8章全球抗糖尿病藥市場:按患者分類

  • 簡介
  • 成人
  • 老年醫學
  • 兒科

第9章美洲抗糖尿病藥市場

  • 簡介
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區的抗糖尿病藥市場

  • 簡介
  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第11章歐洲,中東/非洲糖尿病藥物市場

  • 簡介
  • 法國
  • 德國
  • 意大利
  • 荷蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合酋長國
  • 英國

第12章競爭情況

  • FPNV定位矩陣
    • 象限
    • 經營策略
    • 產品滿意度
  • 市場排名分析
  • 市場份額分析
  • 競爭性SWOT分析
  • 競爭情景
    • 併購
    • 協議,合作和夥伴關係
    • 推出和增強新產品
    • 投融資
    • 獎項,獎項,擴展

第13章企業可用性概況

  • Abbott Laboratories
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • C.H. Boehringer Sohn AG & Co. KG
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
  • Mankind Pharma Ltd
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • PHC Corporation
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
  • Wockhardt Limited

第14章附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-437896AA367B

The Global Antidiabetic Drug Market size was estimated at USD 35.29 Billion in 2020 and expected to reach USD 38.90 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 10.56% to reach USD 64.48 Billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Antidiabetic Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Antidiabetic Drug Market was studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin is further studied across Intermediate-acting Insulin, Long-acting Analog, Premixed Insulin, Rapid-acting Analog, and Short-acting Analog.

Based on Disease, the Antidiabetic Drug Market was studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.

Based on Patient, the Antidiabetic Drug Market was studied across Adult, Geriatric, and Pediatric.

Based on Geography, the Antidiabetic Drug Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antidiabetic Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antidiabetic Drug Market, including Abbott Laboratories, Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, C.H. Boehringer Sohn AG & Co. KG, Cadila Pharmaceuticals Limited, Cipla, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals), Mankind Pharma Ltd, Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TONGHUA DONGBAO PHARMACEUTICAL CO., LTD., and Wockhardt Limited.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Antidiabetic Drug Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antidiabetic Drug Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antidiabetic Drug Market?
  • 4. What is the competitive strategic window for opportunities in the Global Antidiabetic Drug Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Antidiabetic Drug Market?
  • 6. What is the market share of the leading vendors in the Global Antidiabetic Drug Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Antidiabetic Drug Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Patient Outlook
  • 3.4. Type Outlook
  • 3.5. Disease Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Changing lifestyle of people and irregular dietary habits
      • 5.1.1.2. Strong product pipeline of antidiabetics
      • 5.1.1.3. Globally rising prevalence of diabetes and increasing obesity among people
      • 5.1.1.4. Increasing consumer awareness level and improved technology
    • 5.1.2. Restraints
      • 5.1.2.1. Prohibitive cost of Insulin
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
      • 5.1.3.2. Ongoing research and development
      • 5.1.3.3. Governments and private companies to work together for the supply of inexpensive drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Wide availability of antidiabetics drugs
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Antidiabetic Drug Market, by Type

  • 6.1. Introduction
  • 6.2. Alpha-glucosidase Inhibitors
  • 6.3. Biguanides
  • 6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
  • 6.5. GLP-1 (Glucagon-like Peptide) Agonists
  • 6.6. Insulin
    • 6.6.1. Intermediate-acting Insulin
    • 6.6.2. Long-acting Analog
    • 6.6.3. Premixed Insulin
    • 6.6.4. Rapid-acting Analog
    • 6.6.5. Short-acting Analog
  • 6.7. Meglitinides
  • 6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
  • 6.9. Sulphonylureas
  • 6.10. Thiazolidinedione

7. Antidiabetic Drug Market, by Disease

  • 7.1. Introduction
  • 7.2. Diabetes Mellitus Type 1
  • 7.3. Diabetes Mellitus Type 2

8. Antidiabetic Drug Market, by Patient

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Americas Antidiabetic Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Antidiabetic Drug Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Antidiabetic Drug Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Abbott Laboratories
  • 13.2. Aristo Pharmaceuticals Pvt. Ltd.
  • 13.3. Astellas Pharma Inc.
  • 13.4. AstraZeneca PLC
  • 13.5. Biocon Limited
  • 13.6. C.H. Boehringer Sohn AG & Co. KG
  • 13.7. Cadila Pharmaceuticals Limited
  • 13.8. Cipla, Inc.
  • 13.9. Eli Lilly and Company
  • 13.10. F. Hoffmann-La Roche Ltd.
  • 13.11. GlaxoSmithKline PLC
  • 13.12. Glenmark Pharmaceuticals Ltd.
  • 13.13. Halozyme Therapeutics, Inc.
  • 13.14. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
  • 13.15. Mankind Pharma Ltd
  • 13.16. Merck KGaA
  • 13.17. Novo Nordisk A/S
  • 13.18. Oramed Pharmaceuticals Inc.
  • 13.19. Pfizer Inc.
  • 13.20. PHC Corporation
  • 13.21. Sanofi S.A.
  • 13.22. Takeda Pharmaceutical Company Limited
  • 13.23. Teva Pharmaceutical Industries Ltd.
  • 13.24. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
  • 13.25. Wockhardt Limited

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2020 VS 2026 (USD BILLION)
  • FIGURE 2. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 (USD BILLION)
  • FIGURE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 (USD BILLION)
  • FIGURE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 (USD BILLION)
  • FIGURE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
  • FIGURE 6. GLOBAL ANTIDIABETIC DRUG MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL ANTIDIABETIC DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (USD BILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2026
  • FIGURE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, 2018-2026 (USD BILLION)
  • FIGURE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, 2018-2026 (USD BILLION)
  • FIGURE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, 2018-2026 (USD BILLION)
  • FIGURE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, 2018-2026 (USD BILLION)
  • FIGURE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, 2018-2026 (USD BILLION)
  • FIGURE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, 2018-2026 (USD BILLION)
  • FIGURE 26. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 27. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, 2018-2026 (USD BILLION)
  • FIGURE 28. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 29. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, 2018-2026 (USD BILLION)
  • FIGURE 30. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 31. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, 2018-2026 (USD BILLION)
  • FIGURE 32. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 33. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 34. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 35. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, 2018-2026 (USD BILLION)
  • FIGURE 36. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 37. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, 2018-2026 (USD BILLION)
  • FIGURE 38. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 39. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2026 (%)
  • FIGURE 40. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2026 (USD BILLION)
  • FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2026
  • FIGURE 42. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, 2018-2026 (USD BILLION)
  • FIGURE 43. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 44. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, 2018-2026 (USD BILLION)
  • FIGURE 45. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 46. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2026 (%)
  • FIGURE 47. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2026 (USD BILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2026
  • FIGURE 49. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, 2018-2026 (USD BILLION)
  • FIGURE 50. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 51. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, 2018-2026 (USD BILLION)
  • FIGURE 52. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 53. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, 2018-2026 (USD BILLION)
  • FIGURE 54. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 55. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 56. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 58. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 59. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 60. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 61. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 62. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 63. CALIFORNIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 64. FLORIDA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 65. ILLINOIS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 66. NEW YORK ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 67. OHIO ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 68. PENNSYLVANIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 69. TEXAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 70. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 71. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 72. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 73. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 74. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 75. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 76. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 77. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 78. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 79. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 80. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 81. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 82. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 83. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 84. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 85. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 86. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 87. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 88. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 89. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 90. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 91. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 92. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 93. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 94. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 95. GLOBAL ANTIDIABETIC DRUG MARKET: FPNV POSITIONING MATRIX
  • FIGURE 96. GLOBAL ANTIDIABETIC DRUG MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 97. GLOBAL ANTIDIABETIC DRUG MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 98. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIDIABETIC DRUG MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 25. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 26. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 27. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 28. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 29. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 30. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 31. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 32. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 33. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 34. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 35. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 36. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 37. CANADA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 38. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 39. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 40. MEXICO ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 41. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 42. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 43. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 44. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 45. CALIFORNIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 46. CALIFORNIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 47. CALIFORNIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 48. FLORIDA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 49. FLORIDA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 50. FLORIDA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 51. ILLINOIS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 52. ILLINOIS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 53. ILLINOIS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 54. NEW YORK ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 55. NEW YORK ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 56. NEW YORK ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 57. OHIO ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 58. OHIO ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 59. OHIO ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 60. PENNSYLVANIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 61. PENNSYLVANIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 62. PENNSYLVANIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 63. TEXAS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 64. TEXAS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 65. TEXAS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 66. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 67. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 68. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 69. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 70. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 71. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 72. CHINA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 73. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 74. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 75. INDIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 76. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 77. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 78. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 79. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 80. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 81. JAPAN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 82. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 83. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 84. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 85. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 86. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 87. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 88. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 89. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 90. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 91. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 92. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 93. THAILAND ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 98. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 99. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 100. FRANCE ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 101. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 102. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 103. GERMANY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 104. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 105. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 106. ITALY ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 107. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 108. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 109. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 110. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 111. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 112. QATAR ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 113. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 114. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 115. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 116. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 117. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 118. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 119. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 120. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 121. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 122. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 123. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 124. SPAIN ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 125. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 126. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 127. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 128. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 129. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 130. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 131. GLOBAL ANTIDIABETIC DRUG MARKET: SCORES
  • TABLE 132. GLOBAL ANTIDIABETIC DRUG MARKET: BUSINESS STRATEGY
  • TABLE 133. GLOBAL ANTIDIABETIC DRUG MARKET: PRODUCT SATISFACTION
  • TABLE 134. GLOBAL ANTIDIABETIC DRUG MARKET: RANKING
  • TABLE 135. GLOBAL ANTIDIABETIC DRUG MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 136. GLOBAL ANTIDIABETIC DRUG MARKET: SHARE, BY COMPANY, 2020
  • TABLE 137. GLOBAL ANTIDIABETIC DRUG MARKET: MERGER & ACQUISITION
  • TABLE 138. GLOBAL ANTIDIABETIC DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 139. GLOBAL ANTIDIABETIC DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 140. GLOBAL ANTIDIABETIC DRUG MARKET: INVESTMENT & FUNDING
  • TABLE 141. GLOBAL ANTIDIABETIC DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 142. GLOBAL ANTIDIABETIC DRUG MARKET: LICENSE & PRICING
  • TABLE 143. GLOBAL ANTIDIABETIC DRUG MARKET: CONTACT DETAILS